Researchers tied urothelial carcinoma disease biology and outcomes to MYC overexpression, implicating a tumor-intrinsic mechanism for disease progression and treatment resistance. The work (published in a reported study summary) positions MYC as a driver of clinical trajectory and tumor microenvironment behavior, linking inflammatory signaling amplification to age- and disease-associated changes. The report suggests that targeting MYC-related pathways could support adjunct strategies for patients with aggressive disease features, particularly where resistance emerges.